Details for Patent: 9,511,046

Which drugs does patent 9,511,046 protect, and when does it expire?

Patent 9,511,046 protects ABRAXANE and is included in one NDA.

Protection for ABRAXANE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty patent family members in twenty-three countries.

Summary for Patent: 9,511,046

Title:	Methods of treating pancreatic cancer
Abstract:	Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.
Inventor(s):	Desai; Neil P. (Los Angeles, CA), Renschler; Markus (San Francisco, CA)
Assignee:	ABRAXIS BIOSCIENCE, LLC (Los Angeles, CA)
Application Number:	13/794,480
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,511,046
Patent Claim Types: see list of patent claims	Use; Composition; Delivery;

Drugs Protected by US Patent 9,511,046

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol-myers	ABRAXANE	paclitaxel	POWDER;INTRAVENOUS	021660-001	Jan 7, 2005	AB	RX	Yes	Yes					Y

International Family Members for US Patent 9,511,046

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013203699
Brazil	112015016681
Canada	2897589